Rebound to a positive covid rapid test after testing negative; This spontaneous case was reported by a non-health professional and describes the occurrence of COVID-19 (Rebound to a positive covid rapid test after testing negative) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 058F21A, 004M20A and 030L20A) for COVID-19 vaccination.     Concurrent medical conditions included Allergy (Unknown drug history.). Concomitant products included ROSUVASTATIN from 14-Apr-2022 to 09-May-2022 for an unknown indication.   On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 06-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (Rebound to a positive covid rapid test after testing negative). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 10-May-2022 to 14-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (Rebound to a positive covid rapid test after testing negative) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: positive (Positive) Positive and negative (Negative) Negative.         Company comment: This is a spontaneous case concerning a patient of unknown age and gender with no relevant medical history and with vaccine history of receiving first and second dose of mRNA-1273 vaccine with appropriate dosage interval of 28 days, who experienced the unexpected non-serious  event of Covid-19. The event occurred approximately 6 months after the third dose of mRNA-1273 vaccine administration. The event was described as, approximately 6 months after the third dose of mRNA-1273 vaccine administration patient experienced Covid-19 and took Nirmatrelvir + Ritonavir (Paxlovid). On unknown date patient tested negative on Covid-19 test. On unknown date, patient tested positive on Covid-19 test after testing negative. No other information surrounding the event was reported. The outcome of the event was reported as resolving. The current Covid-19 pandemic remain confounder. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a patient of unknown age and gender with no relevant medical history and with vaccine history of receiving first and second dose of mRNA-1273 vaccine with appropriate dosage interval of 28 days, who experienced the unexpected non-serious event of Covid-19. The event occurred approximately 6 months after the third dose of mRNA-1273 vaccine administration. The event was described as, approximately 6 months after the third dose of mRNA-1273 vaccine administration patient experienced Covid-19 and took Nirmatrelvir + Ritonavir (Paxlovid). On unknown date patient tested negative on Covid-19 test. On unknown date, patient tested positive on Covid-19 test after testing negative. No other information surrounding the event was reported. The outcome of the event was reported as resolving. The current Covid-19 pandemic remain confounder. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.